News & Events
February 12, 2018
Tucson-based Critical Path Institute emerging as top drug-research organizationPresident and CEO Dr. Martha Brumfield was recently interviewed by the Arizona Daily Star for a profile on C-Path published February 11. Dr. Brumfield discusses C-Path’s local ties,expanding global reach, and its recent successes, as well as its groundbreaking collaborative research model. The story outlines the work of C-Path’s consortia in the areas of biomarker...
February 5, 2018
Critical Path to TB Drug Regimens (CPTR) 2018 Annual Workshop, postponedCritical Path Institute and Bill & Melinda Gates Foundation have decided to postpone the Critical Path to TB Drug Regimens Workshop (CPTR) 2018 Annual workshop originally scheduled for April 23-25, 2018. This workshop will be rescheduled later in 2018 to better align with deliverables from our programmatic efforts and alleviate some of the logistical challenges...
December 15, 2017
Proceedings from Huntington’s Disease Regulatory Science Consortium (HD-RSC) Kick-Off Meeting, Nov. 6-7, 2017On November 6 and 7, 2017, in Silver Spring, MD, Critical Path Institute and CHDI Foundation welcomed participants from the pharmaceutical industry, academia, regulatory agencies, and advocacy groups to a kick-off meeting for the Huntington’s Disease Regulatory Science Consortium (HD-RSC). The meeting objectives were to solicit input from stakeholders on HD-RSC plans and deliverables, and...
- October 24, 2017
October 9, 2017
Critical Path Innovation MeetingOn September 14, 2017, Critical Path Institute’s (C-Path) Patient-Reported Outcome (PRO) Consortium and Electronic Patient-Reported Outcome (ePRO) Consortium participated in a Critical Path Innovation Meeting (CPIM) at the U.S Food and Drug Administration’s (FDA) White Oak campus in Silver Spring, MD. As stated on FDA’s website, the goals for CPIMs are “to discuss a methodology...